Juno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 4,157 Shares

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 4,157 shares of Juno Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $85.55, for a total transaction of $355,631.35. Following the completion of the sale, the executive vice president now owns 89,614 shares in the company, valued at approximately $7,666,477.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Robert Azelby also recently made the following trade(s):

  • On Thursday, February 8th, Robert Azelby sold 3,497 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.77, for a total transaction of $299,937.69.
  • On Thursday, February 1st, Robert Azelby sold 4,167 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.78, for a total transaction of $357,445.26.
  • On Monday, January 22nd, Robert Azelby sold 102,539 shares of Juno Therapeutics stock. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75.
  • On Wednesday, January 17th, Robert Azelby sold 29,131 shares of Juno Therapeutics stock. The shares were sold at an average price of $68.61, for a total transaction of $1,998,677.91.
  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.96, for a total transaction of $81,647.36.

Shares of Juno Therapeutics Inc (NASDAQ JUNO) traded down $0.26 during trading on Wednesday, reaching $85.82. 2,180,642 shares of the company were exchanged, compared to its average volume of 6,140,000. The company has a market cap of $9,800.00, a PE ratio of -25.32 and a beta of 3.42. Juno Therapeutics Inc has a 52 week low of $19.62 and a 52 week high of $86.28. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01.

A number of brokerages have recently commented on JUNO. Citigroup cut shares of Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 17th. Needham & Company LLC cut shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Maxim Group restated a “buy” rating and set a $56.00 target price on shares of Juno Therapeutics in a report on Thursday, November 2nd. Wells Fargo & Co cut shares of Juno Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 12th. Finally, Wedbush cut shares of Juno Therapeutics from an “outperform” rating to a “neutral” rating in a report on Wednesday, January 17th. Two research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and three have assigned a buy rating to the stock. Juno Therapeutics currently has an average rating of “Hold” and an average target price of $51.20.

A number of institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Juno Therapeutics by 2.1% in the 2nd quarter. Vanguard Group Inc. now owns 6,285,676 shares of the biopharmaceutical company’s stock worth $187,879,000 after purchasing an additional 131,864 shares in the last quarter. Capital International Investors bought a new position in Juno Therapeutics in the 3rd quarter worth about $256,339,000. BlackRock Inc. boosted its stake in Juno Therapeutics by 6.6% in the 4th quarter. BlackRock Inc. now owns 4,834,370 shares of the biopharmaceutical company’s stock worth $220,981,000 after purchasing an additional 299,586 shares in the last quarter. State Street Corp boosted its stake in Juno Therapeutics by 7.4% in the 2nd quarter. State Street Corp now owns 3,236,384 shares of the biopharmaceutical company’s stock worth $96,742,000 after purchasing an additional 222,754 shares in the last quarter. Finally, Orbimed Advisors LLC boosted its stake in Juno Therapeutics by 123.1% in the 3rd quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock worth $91,587,000 after purchasing an additional 1,126,400 shares in the last quarter. Institutional investors own 68.90% of the company’s stock.

WARNING: “Juno Therapeutics Inc (JUNO) EVP Robert Azelby Sells 4,157 Shares” was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/14/juno-therapeutics-inc-juno-evp-robert-azelby-sells-4157-shares.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply